Evaluating time in therapeutic range for hemodialysis patients taking warfarin

Clinical Nephrology

Volumn 83, Issue 2, 2015, Pages 80-85

  Quinn, Laura M ^a,b   Richardson, Robert ^a,b   Cameron, Karen J ^a,b   Battistella, Marisa ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Hemodialysis; Hemorrhage; INR; Thrombosis; TTR; Warfarin

Indexed keywords

ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PHARMACOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; THROMBOSIS; TIME; TIME IN THERAPEUTIC RANGE; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; THROMBOSIS; TIME FACTORS; WARFARIN;

EID: 84923456360     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108400     Document Type: Article

References (26)

1. Finazzi G, Mingardi G. Oral anticoagulant therapy in hemodialysis patients: do the benefits outweigh the risks? Intern Emerg Med. 2009; 4: 375-380. CrossRef PubMed
2. To AC, Yehia M, Collins JF. Atrial fibrillation in haemodialysis patients: do the guidelines for anti coagulation apply? Nephrology (Carlton). 2007; 12: 441-447. CrossRef PubMed
3. Sood MM, Komenda P, Sood AR, Rigatto C, Bueti J. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest. 2009; 136: 1128-1133. CrossRef PubMed
4. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012; 367: 625-635. CrossRef PubMed
5. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009; 20: 2223-2233. CrossRef PubMed
6. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010; 77: 1098-1106. CrossRef PubMed
7. Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003; 64: 603-609. CrossRef PubMed
8. Holden RM, Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3: 105-110. Cross- Ref PubMed
9. Phelan PJ, O'Kelly P, Holian J, Walshe JJ, Delany C, Slaby J, Winders S, O'Toole D, Magee C, Conlon PJ. Warfarin use in hemodialysis patients: what is the risk? Clin Nephrol. 2011; 75: 204-211. CrossRef PubMed
10. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011; 6: 2662-2668. CrossRef PubMed
11. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014; 129: 1196-1203. CrossRef PubMed
12. Holden RM, Clase CM. Use of warfarin in people with low glomerular filtration rate or on dialysis. Semin Dial. 2009; 22: 503-511. CrossRef PubMed
13. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80: 572-586. CrossRef PubMed
14. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376: 975-983. CrossRef PubMed
15. Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis. 2008; 25: 61-66. CrossRef PubMed
16. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69: 236-239. PubMed
17. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis. 2000; 9: 283-292. CrossRef PubMed
18. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003; 15: 213-216. CrossRef PubMed
19. Thomson BK, MacRae JM, Barnieh L, Zhang J, MacKay E, Manning MA, Hemmelgarn BR. Evaluation of an electronic warfarin nomogram for anticoagulation of hemodialysis patients. BMC Nephrol. 2011; 12: 46. CrossRef PubMed
20. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009; 20: 912-921. CrossRef PubMed
21. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165: 1095-1106. CrossRef PubMed
22. Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ. 2007; 177: 369-371. CrossRef PubMed
23. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007; 167: 239-245. CrossRef PubMed
24. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Throbolysis.2014; 38: 150-159. PubMed
25. Nelson WW, Choi JC, Vanderpoel J, Damaraju CV, Wildgoose P, Fields LE, Schein JR. Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2013; 112: 509-512. CrossRef PubMed
26. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood. 2007; 109: 2419-2423. CrossRef PubMed